Northwest Biotherapeutics, Inc.
NWBOOTCHealthcare● Active
$0.20
$-0.01(-2.65%)
Market Cap$325545654
P/E Ratio—
52W High$0.37
52W Low$0.18
Northwest Biotherapeutics, Inc. (NWBO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NWBO · as of 2026-06-13
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.38M | $1.38M | $1.93M | $1.68M | $1.00M |
| Cost of Revenue | $2.34M | $0.00M | $27.73M | $1.55M | $20.31M |
| Gross Profit | ($0.96M) | $1.38M | ($25.80M) | $0.14M | ($19.30M) |
| Gross Margin %(computed) | -69.59% | 100.00% | — | 8.02% | — |
| Operating Expenses | |||||
| R&D Expenses | $28.79M | $34.89M | $27.73M | $35.51M | $20.31M |
| G&A Expenses | $32.51M | $33.00M | $29.71M | $33.35M | $33.40M |
| Total Operating Expenses | $58.95M | $67.89M | $57.44M | $68.86M | $53.71M |
| Operating Income | ($59.91M) | ($66.51M) | ($55.51M) | ($67.18M) | ($52.70M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | ($8.70M) | $7.77M | $5.24M | $6.07M | $5.01M |
| Income Before Tax | ($60.70M) | ($83.78M) | ($62.60M) | ($105.03M) | $179.13M |
| Income Tax Expense | $0.78M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($61.48M) | ($83.78M) | ($62.60M) | ($105.03M) | $179.13M |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.04 | $-0.07 | $-0.06 | $-0.10 | $0.21 |
| Wtd Avg Shares | 1456.66M | 1242.24M | 1119.19M | 1015.85M | 873.52M |
| EBITDA | ($57.58M) | ($73.64M) | ($55.34M) | ($97.42M) | $184.72M |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-13 · USD · M
Explore more Northwest Biotherapeutics, Inc. data
About Northwest Biotherapeutics, Inc. (NWBO) Income Statement
Northwest Biotherapeutics, Inc. (NWBO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NWBO reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -69.59%), and net income of ($0.06B) — a net profit margin of -4461.32%.
Frequently asked questions
NWBO · 4 questionsNorthwest Biotherapeutics, Inc. (NWBO) reported revenue of $0.00B for 2025, down 0.3% year-over-year.
NWBO revenueNWBO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-13